CGEM (Cullinan Oncology) רווח למניה בארבעת הרבעונים האחרונים

The share price of Cullinan Therapeutics (CGEM) visualized below, where the EPS is 10.40, correlates with the company's focus on developing selective anti-tumor agents and licensing fees. The current financial status is based on the depletion of existing reserves to fund costly trials. However, geopolitical tensions and trade barriers could hinder the international certification of technologies and the procurement of necessary components.
Cullinan Oncology - פילוחים אנליטיים ומדדי מפתח (CGEM)

Fundamental asset selection is based on profit dynamics analysis to assess business sustainability. This indicator measures the annual change in earnings per share over a rolling period, identifying growth rates or declines in capital efficiency. For Cullinan Therapeutics (CGEM), which generates no revenue due to the clinical status of its developments, this metric reflects only the dynamics of operating losses. Evaluate these fluctuations using the EPS YoY TTM relative change chart.